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Genetic toxicity tests currently used to identify and characterize potential human mutagens and 
carcinogens rely on measurements of primary DNA damage, gene mutation, and chromosome 
damage in vitro and in rodents. The International Life Sciences Institute Health and 
Environmental Sciences Institute (ILSI-HESI) Committee on the Relevance and Follow-up of 
Positive Results in In Vitro Genetic Toxicity Testing held an April 2012 Workshop in 
Washington, DC, to consider the impact of new understanding of biology and new technologies on 
the identification and characterization of genotoxic substances, and to identify new approaches to 
inform more accurate human risk assessment for genetic and carcinogenic effects. Workshop 
organizers and speakers were from industry, academe, and government. The Workshop focused on 
biological effects and technologies that would potentially yield the most useful information for 
evaluating human risk of genetic damage. Also addressed was the impact that improved 
understanding of biology and availability of new techniques might have on genetic toxicology 
practices. Workshop topics included (1) alternative experimental models to improve genetic 
toxicity testing, (2) Biomarkers of epigenetic changes and their applicability to genetic toxicology, 
and (3) new technologies and approaches. The ability of these new tests and technologies to be 
developed into tests to identify and characterize genotoxic agents; to serve as a bridge between in 
vitro and in vivo rodent, or preferably human, data; or to be used to provide dose response 
information for quantitative risk assessment was also addressed. A summary of the workshop and 
links to the scientific presentations are provided.
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INTRODUCTION
Genetic toxicology testing of chemicals for regulatory agency approval relies on in vitro and 
in vivo tests that measure primary DNA damage, gene mutation, and chromosome damage 
for identification of potential human mutagens and carcinogens. The majority of these tests 
have been in use for more than 30 years. During that time, our understanding of molecular 
biology has increased exponentially, particularly in areas such as epigenetics, noncoding 
RNA, genetic structure, and mechanisms responsible for the maintenance of DNA integrity. 
In addition, technological advances have been made within and outside the field of genetic 
toxicology (e.g., 3-D tissue and organ cultures; high throughput methods; flow cytometric 
analyses; gene expression analysis; imaging) that could permit the measurement of multiple 
parameters for different effects on the genome that lead to mutation or cancer. It is 
recognized that many of these new procedures could be of use in developing or interpreting 
genetic toxicity test results, enabling a better understanding of the mechanism of action of 
chemicals, and improving extrapolation to potential effects in humans.
Despite these advances, the regulatory testing battery has remained relatively unchanged. 
Most countries require new chemicals, including drugs, pesticides, industrial chemicals, and 
food additives, to be tested in (1) an in vitro test for gene mutation in bacteria, (2) an in vitro 
cytogenetic or micronucleus assay with mammalian cells or an in vitro mammalian cell gene 
mutation assay, and in some cases, (3) an in vivo test for chromosomal damage using rodent 
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hematopoietic cells. The measurement of genetic damage is frequently assessed as one of 
the key events in the progression of cancer, although toxicologists recognize that a wide 
spectrum of additional human health effects, including neurological disorders, birth defects, 
and mitochondrial diseases, may also result. These tests are generally not used in a 
quantitative manner (e.g., to provide information on relative potency) but only to provide 
binary, yes/no, information on the genetic hazard of the test substance. It is clear that for 
genetic toxicity testing to progress beyond this yes/no level, new test procedures or 
techniques will be needed that could bridge the gaps between in vitro data, in vivo rodent 
data, and human data for hazard characterization and quantitative risk assessment.
The International Life Sciences Institute/Health and Environmental Sciences Institute (ILSI-
HESI) Project Committee on the Relevance and Follow-up of Positive Results in In Vitro 
Genetic Toxicity (IVGT) Testing1 was formed in 2008 to assess the current state of genetic 
toxicity testing, address issues related to the performance of the assays in use at that time, 
and evaluate new testing techniques and technologies that hold promise for improving on the 
predictive performance of the tests. Additionally, efforts are underway to develop new 
approaches for quantitative analysis of the test data [Gollapudi et al., 2013; Johnson et al., 
2014] and improve hazard and risk assessment for humans.
An initial workshop was convened in May, 2008 to review and assess methods that could be 
used in place of, or in addition to, this test battery for identification and characterization of 
genetically active substances [Lynch et al., 2011]. In that workshop, a number of new and 
emerging in vitro and in vivo test methods were evaluated for their potential utility for 
incorporation into existing testing schemes.
The subsequent April 2012 Workshop2, reported herein, was developed to consider the 
impact that our improved understanding of biology and new technologies might have on the 
identification and characterization of genotoxic substances, to define ways of bridging 
genetic toxicology to other disciplines, and to identify potential synergies that would result 
in new approaches to inform more accurate human risk assessment for genetic and 
carcinogenic effects. The workshop organizers identified tests and test endpoints that are 
being investigated by a number of laboratories and which may have promise for improving 
the identification of potential genetic (and epigenetic) effects, and which may be used in the 
future (and in most cases, upon further development) to replace or supplement the test 
procedures currently in use. To accomplish these goals, the Workshop brought together 
expertise from both within and outside the discipline of genetic toxicology, and experts in 
risk assessment from regulatory agencies were invited to participate and offer perspectives 
on how the new procedures and technologies, including some still in the research phase, 
might be applied to address mutagenic modes-of-action in carcinogenesis and to inform 
quantitative assessment of mutagenic risk.
1Steering committee for this Workshop: M. J. Aardema, L. Custer, B. Gollapudi, M. Honma, M. Manjanatha, S. Pfuhler, L. 
Stankowski, Jr., J. van Benthem, P. White, K.L. Witt, V. Thybaud, E. Zeiger.
2Genetic Toxicology: Opportunities to Integrate New Approaches. April 24–25, 2012. Crowne Plaza Hotel, Silver Spring, Maryland. 
http://www.hesiglobal.org/i4a/pages/index.cfm?pageid=53596
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The genetic and epigenetic effects and the technologies that were selected as topics for the 
Workshop were those that the Organizing Committee believed would potentially yield the 
most useful information relevant to human hazard and risk assessment for genetic damage. 
The participants were also asked to consider the impact that the improved understanding of 
biology and the availability the new techniques might have on genetic toxicology practices. 
Among the general issues discussed were the ability of these new tests/technologies to be 
developed into tests to identify and characterize genotoxic agents; whether the test could 
provide information on in vivo genetic damage or serve as a bridge between in vitro and in 
vivo rodent, or preferably human, data, or be used to provide dose response information for 
quantitative risk assessment. To help better put the new technologies into perspective, the 
presenters were each asked to prepare a SWOT (Strengths; Weaknesses; Opportunities; 
Threats) analysis as part of their presentations, which would then be discussed in detail by 
the Workshop participants (see Tables (I–III)). To maximize the interaction among the 
Workshop participants, time for discussion was allotted after each presentation, and 
extended periods of discussion were provided at the end of each session.
There were 108 Workshop participants from regulatory agencies, government research 
laboratories, industry, and academe, including presenters. A condensed summary of the 
workshop along with links to key scientific presentations is presented in this report. In 
addition, this report also documents the attempts of the genetic toxicology community to 
advance the field by embracing/integrating the advances in various allied scientific 
disciplines over the past 30 years.
WORKSHOP PRESENTATIONS
Overview (V. Thybaud, Sanofi; B. Gollapudi, The Dow Chemical Co. [Cochairs])
The introductory comments to the Workshop participants provided an overview of the 
history of the HESI initiative, the structure of the HESI committee, including its various 
subcommittees and leaders, and the organizing committee, as well as the objectives of the 
Workshop, are available at: http://www.hesiglobal.org/files/public/Committee
%20Presentations/IVGT/2-IVGT-NAWkshpThybaud.pdf.
Session 1: Alternative Experimental Models to Improve Genetic Toxicity 
Testing (M. J. Aardema, BioReliance Corp.; S. Pfuhler, The Procter and 
Gamble Co.)—This session was designed to present and discuss recently developed 
biological models and test systems. Issues addressed included the adaptation of these models 
as tools for genetic toxicity testing and the best use of these models, whether as supplements 
or potential replacements to the genetic toxicity test systems currently in use. The relevance 
of these new models to animal and human exposure scenarios, metabolic capacity, etc., and 
their ability to inform and improve hazard identification and risk assessment decisions was 
evaluated.
Stefan Pfuhler (The Procter & Gamble Co.) described and discussed the use of 3-
dimensional (3-D) tissue constructs for genotoxicity testing. The in vitro genotoxicity tests 
currently used are based on two-dimensional mammalian cell cultures. 3-D tissue constructs 
are logical follow-up tools for genotoxicity testing because they allow for more natural cell-
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cell and cell-matrix interactions, and show “in vivo-like” behavior for key parameters such 
as cell viability differentiation, morphology, gene and protein expression, and function. 
These constructs are available at various levels of complexity from simple (e.g., epidermal 
skin models with only one cell type) to highly complex (e.g., vascularized human liver 
model). 3-D skin models have been successfully established for testing for genotoxic 
properties of dermally applied compounds using micronucleus and Comet assays. Several 
liver culture systems were also presented and their potential use in genotoxicity testing was 
discussed. Details of this presentation can be viewed at http://www.hesiglobal.org/files/
public/Committee%20Presentations/IVGT/4%Pfuhler.pdf).
Seiichi Ishida (National Institute of Health Sciences) discussed the development of in vitro 
toxicity tests using hepatocytes differentiated from human induced pluripotent stem cells 
(http://www.hesiglobal.org/files/public/Committee%20Presentations/IVGT/5-
ISHIDAshorten.pdf). Pluripotent stem cells, including those from humans, have the 
potential to differentiate into tissue-specific primary cells, which could be used for genetic 
toxicity studies. Several kinds of stem cells are considered suitable. However, their use had 
been limited because of their availability and accessibility, and because of ethical issues 
regarding their source. The situation has changed since the establishment of the human iPS 
(induced pluripotent stem) cell line. Differentiation of iPS cells into hepatocytes could make 
possible an unlimited and uniform supply of a variety of cells with different genetic 
backgrounds.
Darrell Boverhof (The Dow Chemical Co.) described the construction and use of humanized 
animal models (http://www.hesiglobal.org/files/public/Committee%20Presentations/
IVGT/6-Humanized_Models-DRB-FINAL.pdf). Humanized models can be defined as 
animal models that carry functioning human genes, cells, tissues, or organs, and include 
transgenic animals that express human genes or immunodeficient animals that have been 
engrafted with human cells or tissues. The models have been applied in research areas such 
as hematopoiesis, innate and adaptive immunity, autoimmunity, infectious disease, cancer 
biology, regenerative medicine, pharmacology, and toxicology. Two applications are 
humanized metabolizing enzyme models and nuclear receptor models. These, and other, 
models have provided valuable insights into human-specific responses and modes of action 
that can be used to decrease uncertainties in human hazard and risk assessments. Although 
these models have traditionally been limited to the mouse, new technologies are facilitating 
the development of models in other species.
Session 2: Biomarkers of Epigenetic Changes and Their Applicability to 
Genetic Toxicology (B. Gollapudi, The Dow Chemical Co.; V. Thybaud, Sanofi)
—It is generally recognized that epigenetic changes to the DNA, while not causing a change 
in the nucleotide composition or sequence, can lead to heritable phenotypic changes, 
including heritable changes in the newborn. This session was organized to discuss the 
potential interplay between chemically induced alterations to the genome (genetic toxicity) 
and changes to the epigenome leading to or exacerbating heritable effects. This session 
considered screening systems that can be designed to identify “epimutations” and to 
evaluate the potential for their transgenerational inheritance, and whether new, less invasive 
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and hopefully transspecies biomarkers of exposure, susceptibility, and effect can be 
identified in order to contribute to the risk assessment process.
Peter Dedon (Massachusetts Institute of Technology) described studies on the dynamic 
reprogramming of tRNA modifications and their effects on the stress response (http://
www.hesiglobal.org/files/public/Committee%20Presentations/IVGT/8-
DedonHESIGentoxWorkshop.pdf). Complex interactions between tRNA, mRNA, and 
ribosomes control the rate and fidelity of translation. Contributing to this are the large 
numbers of genes encoding tRNAs, rRNA and proteins, in addition to different 
ribonucleoside modifications. The modified ribonucleosides in tRNA behave as a system, 
and are reprogrammed in response to different types of cell stress. When cells are exposed to 
toxicants there are dynamic shifts in the population of RNA modifications as part a step-
wise mechanism of cell responses to the chemical stresses and damage, with signature 
changes for each agent and for different doses of each agent. These responses involve 
reprogramming of tRNA modifications that leads to reprogramming of ribosome structure in 
the translational control of cellular stress responses.
Jennifer Marlowe (Novartis) described studies of the potential use of epigenetics in 
toxicology (http://www.hesiglobal.org/files/public/Committee%20Presentations/IVGT/9-
IVGT%20meeting_24Apr2012_JMarlowe_Final.pdf). Some of the earliest events preceding 
the development of overt pathologies, including those arising from exposure to 
environmental and pharmaceutical agents, involve perturbations of the epigenome. The 
application of epigenomic profiling technologies to drug safety sciences has potential for 
providing novel insights into the molecular basis of long-lasting cellular perturbations. 
Genome-wide epigenomic and transcriptomic profiling, combined with molecular 
histopathology, are valuable components towards investigation of temporal sequences of 
events, and therefore mechanistic understanding of the toxicity response. Integrated 
molecular profiling that can be performed includes analyses of mRNA, microRNA, DNA 
methylation, and proteins. The mapping of epigenomes from humans and other species will 
enhance our ability to interpret the biological significance of xenobiotic-induced epigenetic 
perturbations, and may provide novel biomarkers for susceptibility to adverse events.
Igor Pogribny (US Food and Drug Administration) addressed epigenetic traits as biomarkers 
of carcinogenesis (http://www.hesiglobal.org/files/public/Committee%20Presentations/
IVGT/10-Pogribny_ILSI_2012.pdf). Numerous epigenetic responses that may be used as 
potential biomarkers for the molecular diagnosis of cancer and prognosis for survival or 
treatment outcomes have been identified. Epigenetic alterations may be used as early 
indicators in the evaluation of the carcinogenic potential of both genotoxic and 
nongenotoxic substances. Incorporation of epigenetic biomarkers into cancer risk 
assessment holds a number of advantages over traditionally used methods, such as 
evaluation of DNA damage, DNA adduct formation, or bacterial mutagenicity. These 
advantages include their earlier appearance, stability, target tissue-specificity, and 
applicability to both genotoxic and nongenotoxic agents. In addition, a greater number of 
detectable epigenetic changes than detectable genetic alterations are present after exposure 
to the insult.
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Andrea L. Kasinski (Yale University) described studies on the use of microRNAs (mRNAs) 
for treatment of lung cancers (http://www.hesiglobal.org/files/public/Committee
%20Presentations/IVGT/11–042412Kasinski.pdf). Because they are endogenous substances, 
toxicities associated with mRNA use are expected to be minimal. Different delivery agents 
for these regulatory molecules are being investigated, and studies are ongoing to better 
understand their therapeutic potential, notably in the context of cancer. Targeted therapies 
have shown encouraging results for subsets of lung cancer patients. Likewise, gene therapies 
using retrovirus and replication-impaired adenoviruses to reintroduce the tumor suppressive 
protein p53 have had compelling results, including tumor regression and stabilization.
Session 3: New Technologies and Approaches (M. Manjanatha, US Food and 
Drug Administration; K. L. Witt, National Institute of Environmental Health 
Sciences)—This session was organized to present technology-driven approaches to 
assessing genetic toxicity, including the potential mode-of-action leading to the effect. There 
are a number of new initiatives and advances in the field of toxicology, ranging from high 
resolution, high content imaging assays to high throughput approaches that allow the 
profiling of thousands of chemicals in multiple, diverse assays. It is important from both 
scientific and strategic points of view that genetic toxicologists understand the implications 
and impact of these new technologies and embrace those approaches that hold the greatest 
promise for improving genetic toxicity hazard and risk assessment.
William Slikker (US Food and Drug Administration) addressed new imaging techniques that 
could be used in safety assessment of chemicals (http://www.hesiglobal.org/files/public/
Committee%20Presentations/IVGT/14-
SlikkerImagingGenetoxIVGTconference041512.pdf). Although the use of imaging in the 
clinical setting is well established, the use of imaging for preclinical assessments is 
infrequent. Positron Emission Tomography (MicroPET) can be used to assess any target 
organ and deliver quantitative information in a minimally invasive manner and in parallel 
with other endpoint requirements. One advantage to this approach is that the animal can be 
used as its own control. A number of dose-response studies were performed of CNS 
responses to anesthetic drugs. The data from these studies support the concept that imaging 
is a viable approach for assessing nervous system status by serving as a minimally invasive 
and translatable bio-marker. Similar imaging techniques may find use in the identification of 
precarcinogenic changes in organs of animals treated with carcinogenic chemicals or subject 
to cancer-inducing stress conditions.
Raymond Tice (National Institute of Environmental Health Sciences) described the Tox21 
interagency (NIEHS, NHGRI, EPA, and FDA) studies on the responses of ~100 quantitative 
high throughput screens (qHTS), predominantly reporter gene assays using a 1536-well 
format on an automated platform (Phase I) (http://www.hesiglobal.org/files/public/
Committee%20Presentations/IVGT/15-Tice-ILSI-HESI_GeneTox.pdf). Among the qHTS 
assays were several that related to the detection of activities associated with some aspect of 
genotoxicity. Phase II of the program screened a 10,000 compound library against a set of 
nuclear receptor and stress response pathway assays, to detect potentially genotoxic 
compounds. Confirmation of genotoxicity of a small set of selected compounds will be 
performed using standard in vivo tests. The lack of xenobiotic metabolism in the qHTS 
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assays is a major limitation, so protocols that use metabolically competent cells are being 
developed to address this limitation. Data from these assays will be compared against 
existing in vitro genotoxicity data. All the data generated through Tox21 are available 
through a variety of publicly accessible databases.
Scott Auerbach (National Institute of Environmental Health Sciences) discussed the effect of 
dose level and exposure duration on genomic signatures in response to chemical exposure 
(http://www.hesiglobal.org/files/public/Committee%20Presentations/IVGT/16-Auerbach-
IVGT-2012-3.pdf). One potential approach to the problem of setting protective exposure 
limits for toxic responses is the use of in vivo toxicity testing coupled with toxicogenomic 
dose-response analysis. Typically, the most important piece of information acquired from 
these studies is the benchmark dose (BMD). A systematic assessment of no-observed-effect 
levels indicates that they change minimally going from subacute to chronic exposures. The 
application of genomics allows for a broad-based query of biological perturbations that is in 
line with the goals of safety testing, as it is an agnostic query of nearly all the possible 
changes at the level of the transcriptome. Results from studies of specific agents suggest 
that, depending upon the mode of action, genomic signatures can identify less sensitive, in 
the case of genotoxic agents, or more sensitive, in the case of nongenotoxic agents, BMD 
values when compared with the values from tumor response data.
DISCUSSION
The disciplines of genetic toxicology and genetic toxicity testing were originally designed 
and developed for hazard identification. This was based on the presumption that 
identification of genotoxic substances would allow society to avoid or minimize exposure to 
agents that induce mutations in somatic and germ cells, and thereby contribute to the efforts 
to prevent cancer formation and other adverse effects in exposed and future generations. 
These uses of genetic toxicity data have not changed significantly for more than 30 years. 
The identification of substances posing a genetic hazard would also contribute to the risk 
assessment and risk management decisions.
For the field of genetic toxicity testing to move beyond the traditional test endpoints and 
binning of test responses into “positive” and “negative” it will be necessary to either 
improve the existing assays or apply new approaches used in other biology domains, and to 
“think outside of the box.” These new approaches would employ new experimental models 
and technologies and incorporate our growing understanding of the relevant biological 
mechanisms responsible for the development of a mutated cell and its contribution to 
adverse health effects (e.g., cancer).
This Workshop addressed how the new scientific discoveries and methodologies could allow 
for more effective and relevant screening of chemicals and other environmental substances 
for mutagenic risk and resulting health issues. There are a large number of test methods, 
testing approaches, and technologies that can potentially address these issues. However, 
because of time and other constraints, only a few could be addressed at the Workshop, and 
the lack of inclusion of other biological end-points and techniques was not meant to imply 
that they would be less useful. Included among the methods discussed in the Workshop were 
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those that measured the traditional genetic endpoints (e.g., micronuclei, DNA and 
chromosome breaks, and gene mutation), but more efficiently or in cell, tissue, or animal 
constructs that are deemed to be more relevant to human exposure than the traditional test 
systems. The integration of new, nontraditional methods concentrated on the relevance and 
use of epigenetic changes as biomarkers of heritable genetic damage or cancer without the 
underlying change in DNA sequence. In addition, new detection techniques amenable to 
high-throughput screening, and noninvasive in vivo approaches, were presented. It was 
recognized that not all of the models addressed at the workshop appeared to be directly 
applicable to genetic toxicology or cancer initiation. However, the structure of the workshop 
and the presentations served as much to introduce the researchers and developers to the 
issues and needs of genetic toxicology, as they did to introduce the genetic toxicologists to 
the newly emerging models.
Although there were a number of discussions and suggestions of how the various test 
procedures might be used as adjuncts or alternatives to the current test guidelines, it would 
have been premature to make such recommendations, given the experimental nature or lack 
of validation of some of these procedures. As a result, no specific recommendations were 
made with regard to the future use or role of these procedures or whether they should, or 
could, be integrated into the existing testing schemes or replace currently used methods. It 
was clear that, in the future, genetic toxicology scientists will have to use more complex, 
often patented, commercially available models and technologies.
The Workshop participants identified issues and knowledge gaps that will require more 
work and resources, and that would best profit from collaborations between genetic 
toxicologists and the new technology researchers. The conclusions of the presenters and the 
discussions during and at the end of the Workshop are presented in the SWOT analyses (see 
Tables (I–III)) developed for the individual test approaches and assays and which were 
agreed to be a useful approach for evaluating the potential suitability of a process or test 
procedure.
Remaining issues and knowledge gaps identified by the Workshop included:
• The relevance of surrogate models, and the ability of these models to mimic human 
cells and whole body complexity, with respect to DNA repair, metabolic activation, 
and genetic stability;
• The relevance of the various identified end-points for human risk assessment and 
the ability to extrapolate the results from these models to humans based on 
protective mechanisms and genetic polymorphisms, including the identification of 
appropriate safety and uncertainty factors;
• The need to consider all key events, including epigenetic factors, that might 
contribute to DNA damage or modification and affect the organism’s response to 
these DNA effects and DNA integrity;
• Whether and how multiparametric and more integrated test methods can help 
improve our understanding of genotoxic modes of action.
Zeiger et al. Page 9
Environ Mol Mutagen. Author manuscript; available in PMC 2015 October 21.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
The presentations and discussions at this Workshop have helped to stimulate ongoing efforts 
to develop and refine additional methods of identifying genotoxicants and will provide 
valuable information for the future paradigm of genetic toxicology testing. An ongoing 
activity of the ILSI/HESI IVGT (now named the Genetic Toxicology Technical Committee) 
is to start from a “clean sheet” to determine what a new and improved testing strategy for the 
identification and evaluation of genotoxicants might look like, based on both the current 
practices, and on new and developing approaches. This new testing strategy would be 
developed to cover all aspects of genomic damage, incorporate the advances in systems 
biology, be relevant to human risk assessment and resource efficient, and move away from a 
standard battery approach to a more flexible testing strategy.
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TABLE I
Session 1 SWOT Analyses: Alternative Experimental Models to Improve Genetic Toxicity Testing
Test/system Strengths Weaknesses Opportunities Threats
Three-
Dimensional
Tissue
Constructs
Closer (than 2-D) to “in
vivo” conditions.
Technology is well-
developed and 3-D models
are commercially available.
Cells are of human origin
and function more organ-
like in terms of cell viability,
proliferation, differentiation,
morphology,
gene and protein expression.
Large interest in assay, used
by increasing number of
laboratories in various
locations.
(Pre)validation exercise
ongoing for 3-D skin.
More difficult to handle 
than
2-D.
High throughput possible
only for low-complexity
models.
Various levels of 
supporting
data available, minimal 
to
moderate.
Used in limited number 
of
labortories.
Some models in early 
stage
of development.
Validation is needed for
most models.
Cost.
3-D constructs have the
potential to serve as
follow-up assays based on
results in the traditional 2-
D tests, especially when
2-D models cannot be
used.
Collaborative efforts 
recommended
for relevant tissues
for which such
efforts are not currently
ongoing (liver, lung).
May be useful to bridge gap
between in vitro and in
vivo for quantitative risk
assessment.
Validation of methods 
is
very resource intense.
Limited availability of 
tissue
constructs.
Potential issues with 
patents.
Stem cell-derived
hepatocytes
Theoretically unlimited supply
of human hepatocytes.
Use of hepatocytes with 
different genetic back-
grounds.
Use of hepatocytes from
patients suffering specific
diseases.
Simultaneous analysis of
multiple drug metabolism
cascade in one cell.
Complexity of 
differentiation
process of stem cells into
hepatocytes.
Low reproducibility of 
differentiation process.
Interlaboratory 
reproducibility
needs to be defined.
Early stage of 
development.
Cost.
Replacement of human primary
hepatocytes.
Replacement/reduction of
animal toxicity testing.
Improvement of hepatotoxicity
prediction.
Evaluation of hepatotoxicity,
prediction of metabolites,
of induction of drug
metabolism-related
enzymes, and of drug-
drug interaction.
Supply of metabolites for
other testing.
Complexity of 
differentiation
process.
Requirements of 
higher maturation
of hepatocyte
activities.
Establishment of 
standards
for hepatocyte 
qualification.
Hepatocyte progenitor 
cell
line: HepaRG.
Ethical and regulatory 
issues
if from human origin.
Humanized animal
models
Allows for better 
characterization
of human hazard
and risk potential.
Relevant to humans.
Provides data on mode/
mechanism of action.
Allows comparison of rodent
vs. human metabolism and
toxicity pathways.
Involves animal use.
Expensive to create and
maintain.
Low-throughput.
Models human gene 
product
in mouse environment.
Refinement of hazard and
risk assessments:
decreased uncertainty
increased human relevance
New technologies are
decreasing the cost and
expanding the model species.
Can be used to further define
“toxicity pathways”
thereby facilitating development
of in vitro assays
based on MoA.
Can be used to validate in
vitro hypotheses.
Models not widely 
available.
Models using different
technologies may 
generate
different results.
Lack of acceptance of 
this
technology for 
advancing
human health risk
assessments.
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TABLE II
Session 2 SWOT Analyses: Biomarkers of Epigenetic Changes and their Applicability to Genetic Toxicology
Test/System Strengths Weaknesses Opportunities Threats
Epigenetic control
of cell
phenotype
Assay is predictive of 
chemical
exposures, including
genotoxins.
Analysis of RNA 
modification
spectra provides
insights into mechanisms
of toxicity.
Possible complementation to
transcriptional and 
proteomic
data for identifying
genotoxic and nongenotoxic
carcinogens.
Relatively straightforward
method for practitioners
of analytical chemistry.
Analysis of RNA 
modification
spectra in very early
stages of development.
Very limited data for 
toxicants.
Relatively specialized
method at this point.
Probably not entirely
predictive of 
carcinogenicity of
a chemical or drug candi-
date.
Interlaboratory validation
will be needed.
Possible coordination of 
RNA
modification analysis with
other ‘omic data sets.
Application to in vitro 
screening
for hazard assessment.
Provides insights into 
mechanisms
of action of toxicants.
Possible biomarkers that 
are
specific for non-genotoxic
carcinogens.
Allow distinction between
genotoxic and 
nongenotoxic
carcinogens.
Analysis of RNA 
modification
reprogramming is in
the earliest stages of 
scientific
acceptance and
application.
Translation to a high-
throughput method.
Relating RNA 
modification
patterns to specific
toxicities.
Epigenetics Provides comprehensive
view of modifications or
changes that may precede
events that lead to 
phenotypic
change or toxicity.
Rich biomarker resource.
Potential for assessment of
species-specific responses
in vivo and in vitro.
Large and complex 
datasets;
need for customized
bioinformatic tools.
Huge number of changes
observed many possible.
mechanisms/outcomes
High probability for
nonspecific or irrelevant
responses.
Distinguishing stress
responses from chemical-
specific responses.
Biomarkers for use in acute 
and
subchronic toxicity studies.
Early prediction of 
genotoxic
risk; inform or replace 2-
year
bioassay.
Drug-induced vs. non-
drug-
induced tumors.
Provide or support 
carcinogen
mode-of-action 
determinations.
May allow identification of 
pre-
neoplastic changes.
Tremendous complexity 
with
possibility of compound-
specific effects rather than
class-effects amenable to
generalized biomarkers
generation.
Translation of findings 
from
preclinical models/results
to humans.
Epigenetic traits as
biomarkers of
carcinogenesis
Early appearance of 
epigenetic
carcinogen-alterations.
Target tissue specificity.
Specificity for genotoxic and
nongenotoxic carcinogens.
Cellular epigenome 
individual
and dynamic variability 
not
completely
characterized.
Models for safety 
assessment
not yet developed.
Endpoints and techniques 
for
use in safety assessment
not established.
Interlaboratory 
reproducibility
not determined.
Early prediction and 
identification
of hazardous compounds
before their dissemination
into environment.
Provide or support 
carcinogen
mode-of-action
determinations.
Complexity of cellular 
epi-
genomic landscape and
epigenetic regulatory
mechanisms.
Correlating epigenomic
changes between test 
animal
species and humans.
MicroRNA 
analysis with
lentivirus platform
This analysis provides data
to progress towards more
clinically relevant 
therapeutic
applications.
The lentivirus system used is
commercially available
and serves as a proof-of-
concept to move forward.
Lentivirus platform 
explored
may not be the best plat-
form for human patient
delivery.
Provides background for
developing and evaluating 
better
and more clinically 
relevant
miRNA delivery 
mechanisms.
Lack of approval for use 
of
lentivirus in humans for
ethical reasons.
Advancement of better,
clinically relevant 
delivery
agents needed.
Multiple companies on 
board
with the development
phase.
Patent protection and
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Test/System Strengths Weaknesses Opportunities Threats
confidentiality agreements 
limit
access.
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TABLE III
Session 3 SWOT Analyses: New Technologies and Approaches
Test/system Strengths Weaknesses Opportunities Threats
Imaging for
safety
assessment
Longitudinal study design
and minimal invasiveness.
Acceptance of imaging by
the medical community
enhances its utility as a
translatable pre-clinical
biomarker.
Can be highly quantitative.
Minimally to noninvasive.
The test animal or human
subject can serve as its
own control.
No standardized approach.
Deficits in quantization.
A powerful technology 
looking
for an application for
genetic toxicology and
carcinogenesis.
Broad applications due to
recent advances in resolution
and standardization of
approaches.
Identification of early toxic
or precarcinogenic
changes in situ.
Expensive technology.
Not universally available.
Tox21 strategy
for detecting
genotoxicants
Capability to test 
thousands
of chemicals in human, or
other species, cells.
Very small amounts of
compound needed for 
screening.
Rapid generation of test
data.
Eliminates or greatly 
reduces
use of animals.
Large number of cell lines
can be used.
Provides MOA 
information.
High throughput screens
currently lack means to 
provide
bioactivation.
Limited number of suitable
genotoxicity assays 
currently
available.
Tested compounds limited 
to
those that are DMSO-
soluble, nonvolatile, stable
in solution for a period of
time, etc.
No or limited, evaluation of
metabolites.
Expensive.
Data processing complexity
heavily software
dependent.
Ability to develop
approaches to assess 
differential
susceptibility on
a wide-spread scale.
Ability to identify susceptible
subpopulations using
genomic assays.
Ability to develop
comprehensive profiles of
chemical activity.
Ability to develop SAR and
chemical clustering models
based on chemical
activity.
Potential to reduce the number
of animals needed for
toxicity testing.
Challenges in anchoring
chemical profiles for
genotoxicity-associated
activity generated with
these technologies to
results from traditional
tests for genotoxicity with
sufficient accuracy to be
acceptable to regulatory
agencies.
Biological relevance and
reliability of the selected
assays for risk assessment.
Reproducibility across cell
lines.
Genomic
Signatures of
Genotoxicity
Query large swaths of 
biological
space in one assay.
Provides pathway/
mechanistic
information.
In vivo genomics dependent
on animals.
Ability to interpret complex
data.
Variability (time-
dependent,
platforms, dose).
Lack of mechanistic 
anchoring
(need more correlative
data).
High dimensionality allows
for querying of large
amount of biological
space including genotoxicity
and beyond (i.e., one
assay to query all).
Potential to rapidly identify
a no-effect dose.
Potential to reduce the numbers
of animals needed to
characterize toxicities.
Metrics (i.e., genes and 
path-
ways) are different from
traditional endpoints.
If it is not possible to
change metrics (i.e.
pathology to pathways), it
will significantly hinder
development in the 
regulatory
arena.
Reproducibility of results
across testing platforms
and between laboratories.
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